key: cord-1026832-648r94o8 authors: Ooi, Kean Hean; Tay, Jie Wen Douglas; Teo, Seok Yee; Liu, Mengying Mandy; Kaewsapsak, Pornchai; Jin, Shengyang; Gao, Yong-Gui; Tan, Meng How title: A CRISPR-based SARS-CoV-2 diagnostic assay that is robust against viral evolution and RNA editing date: 2020-07-03 journal: bioRxiv DOI: 10.1101/2020.07.03.185850 sha: 009acb86157053fb24a39e5ea3354a3608c9fef5 doc_id: 1026832 cord_uid: 648r94o8 Extensive testing is essential to break the transmission of the new coronavirus SARS-CoV-2, which causes the ongoing COVID-19 pandemic. Recently, CRISPR-based diagnostics have emerged as attractive alternatives to quantitative real-time PCR due to their faster turnaround time and their potential to be used in point-of-care testing scenarios. However, existing CRISPR-based assays for COVID-19 have not considered viral genome mutations and RNA editing in human cells. Here, we present the VaNGuard (Variant Nucleotide Guard) test that is not only specific and sensitive for SARS-CoV-2, but can also detect the virus when its genome or transcriptome has evolved or has been edited by deaminases in infected human cells. We show that an engineered AsCas12a enzyme is more tolerant of mismatches than wildtype LbCas12a and that multiplexed Cas12a targeting can overcome the presence of single nucleotide variations. Our assay can be completed in 30 minutes with a dipstick for a rapid point-of-care test. ). For all the tested enzymes, the viral sequence was 145 consistently and clearly detected in every replicate when 20,000 or more copies of RNA were 146 used as input to RT-LAMP. However, in contrast to the published report 15 , when 2,000 147 copies of RNA were used in a 25μl RT-LAMP reaction (i.e. 80 copies per μl) instead, the 148 viral sequence was detected in only around half the replicates for all the Cas enzymes, 149 including LbCas12a. Subsequently, we asked how the sensitivity of the CRISPR-based assay would be affected if 152 we varied the parameters of the LAMP reaction ( Fig. 2 and Supplementary Fig. 3 ). When we 153 decreased the duration of LAMP from 20 to 12 minutes, we observed that the fluorescence 154 signal showed an exponential decay with every 10-fold reduction in RNA copy number, 155 indicating that the analytic limit of detection (LoD) became poorer if the amplification step 156 was performed for too short a period of time. Interestingly however, when we increased the Importantly, no cross-reactivity for SARS-CoV or MERS-CoV was observed regardless of 204 the Cas12a nuclease used. Furthermore, we found that the minimum spacer length for the S2 205 gRNA was 20nt, as shortening of the spacer reduced the collateral activity of all tested 206 nucleases, although unexpectedly, the 18nt gRNA gave higher fluorescence signals than the 207 19nt gRNA. We sought to determine how mismatches at the S2 gRNA-substrate interface may affect the 210 collateral activity of the Cas12a enzymes. To this end, we generated ten additional gRNAs 211 with each harbouring a point mutation at different positions along the spacer (Fig. 4b) . 212 Interestingly, we found from the trans-cleavage assay that individual mismatches at the S2 213 locus affected the collateral activity of all the Cas12a endonucleases much less than those at 214 the N-Mam locus ( Fig. 4c and Supplementary Fig. 9 ). Nevertheless, enAsCas12a and enRVR 215 again exhibited the highest tolerance for mismatches, while wildtype LbCas12a was again the 216 most sensitive to imperfect base pairing between the gRNA and its target substrate. Besides searching for Cas-gRNA pairs that are not only specific for SARS-CoV-2 but are 236 also tolerant of mismatches at the binding site, another strategy to enhance robustness is to 237 incorporate two or more distinct gRNAs into the detection module. As a proof-of-concept, we 238 sought to buffer the collateral activity of LbCas12a, which appeared to be more sensitive to 239 imperfect base pairing at the gRNA-target interface than AsCas12a and its engineered 240 variants. Moreover, LbCas12a protein is commercially available and can be readily bought by 241 diagnostic laboratories that do not have the ability to purify their own enzymes. To keep all 242 the target sites within the same LAMP products, we may pair the S2 gRNA with either the S1 243 or the S3 gRNA, as both worked well with LbCas12a ( Fig. 3b and Supplementary Fig. 6 ). We 244 then tried to design LAMP primers using the online software PrimerExplorer V5. However, 245 we were unable to find any set of primers that would produce an amplicon smaller than 246 500bp that contained both the S2 and S3 loci. In contrast, many primer sets could be obtained 247 for S1 and S2. Hence, we decided to perform our multiplexed targeting experiments with the 248 S1 and S2 gRNAs. Using a synthetic DNA fragment of the SARS-CoV-2 S gene as substrate, we first assessed 251 the collateral activity of our five purified Cas12a enzymes when they were combined with 252 both the S1 and S2 gRNAs. All five nucleases exhibited robust activity with perfect matched 253 (PM) gRNAs ( Fig. 4f and Supplementary Fig. 11 ). However, we noted that addition of the S1 254 gRNA caused a small but obvious reduction in the trans-cleavage activity of the three 255 AsCas12a variants, while that of LbCas12a remained approximately the same. This was 256 likely because the S1 gRNA would compete with the S2 gRNA for the Cas proteins but only 257 LbCas12a exhibited strong activity with the S1 gRNA ( Fig. 3b and Supplementary Fig. 6 ). Subsequently, we profiled the activity of the Cas12a nucleases when the S1 PM gRNA was (Fig. 6b) . Hence, in total, the entire assay took slightly under 30 minutes to complete. Here, 300 we focused on LbCas12a to demonstrate the utility of multiplex targeting. The S2 gRNA (PM 301 or MM10) was used in the assay with or without a second S1 PM gRNA. We also tested 302 different copy numbers of the synthetic SARS-CoV-2 RNA template. Overall, we found that 303 our lateral flow assays gave results that mirrored those from a microplate reader. When the 304 S2 PM gRNA was used alone or in conjunction with the S1 PM gRNA, dark bands appeared 12 at the test line in the presence of at least 200 copies of template in the reaction mix. 306 Expectedly, without any multiplexing, introduction of a mismatch at the S2 gRNA-target 307 interface dramatically reduced the intensity of the test bands and worsened the analytic LoD 308 to 2,000 copies per reaction. Importantly, addition of the S1 PM gRNA was able to partially 309 restore the intensity of the test bands. Quantification of the test and control band intensities 310 further provided a more objective measure of whether the intended target was detected or not. In the case of a mismatch at the S2 locus but perfect base pairing at the S1 locus, we were There is an urgent healthcare need for rapid and accurate diagnostic tests for COVID-19. What initially started as an infectious disease confined to Wuhan, China has since spread to CRISPR-Dx has the potential to meet society's need for such a diagnostic test. The entire 330 workflow consists of four main modules (Fig. 6a) . First is the sample input. Although 331 purified RNA is ideal for performance, the process of RNA extraction will take up precious 332 time, increase cost, and stress the supply chain. Therefore, there is great interest in 333 developing assays that can directly handle patient samples, including nasopharyngeal swabs 334 and saliva. The second module is the isothermal amplification step, which is commonly While promising, current CRISPR-Dx assays for COVID-19 (Table 1) with the fluorescence measurements here taken after 10 minutes using a microplate reader. Data represent mean ± s.e.m. (n = 3-5 biological replicates). Field-deployable viral diagnostics using CRISPR-Cas13 CRISPR-Cas12-based detection of SARS-CoV-2 Massively multiplexed nucleic acid detection using Cas13 SARS-CoV-2 detection with CRISPR diagnostics Genome Composition and Divergence of the Novel Coronavirus (2019-689 nCoV) Originating in China DNA detection using 692 recombination proteins Helicase-dependent isothermal DNA amplification Detection of unamplified target genes via CRISPR-Cas9 immobilized 696 on a graphene field-effect transistor Isothermal Amplification Method for Rapid Detection of SARS-CoV-2 The Architecture of SARS-CoV-2 Transcriptome